Igor Puzanov

2 ta ish

Georgetown University

1. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

   Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +26

   Maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.047644

2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

   Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider +26

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.769170